IP Verse

Amgen Research Munich competitive analysis

Latest patents of Amgen Research Munich opposed by its competitors

Explore Amgen Research Munich's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP3611193
Aug 26, 2026Binding Molecules For Bcma And Cd31
EP3819007
Jul 10, 2024Dosing Regimen For Anti-Bcma Agents3
EP2637670
Mar 13, 2024Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains3
EP4058148
Mar 13, 2024Dosing Regimen For Anti-Bcma Agents3
EP3531133
Aug 23, 2023Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients1
EP2352763
Sep 21, 2022Bispecific Single Chain Antibodies With Specificity For High Molecular Weight Target Antigens1
EP3411402
Dec 22, 2021Bcma And Cd3 Bispecific T Cell Engaging Antibody Constructs1
EP2632954
Jul 7, 2021Means And Methods For Treating Dlbcl1
EP2493503
Jan 20, 2021Dosage Regimen For Administering A Cd19Xcd3 Bispecific Antibody1
EP3228315
Nov 25, 2020Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains2

Latest PTAB cases involving Amgen Research Munich

Discover the latest PTAB cases involving Amgen Research Munich, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Amgen Research Munich with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
AMGEN RESEARCH MUNICH - 40 - -
JAMES POOLE204 - - -
JANSSEN BIOTECH152116
REGENERON PHARMACEUTICALS55153932